-
-
-
- WHX Labs Dubai 2026
- analytica 2026
- Forum Labo 2026
- SLAS Europe 2026
- Forum Labo 2026 Bioprocess
- Bioprocessing Summit Europe 2026
- BioProcess International 2026
- Swiss Biotech Day 2025
- ISCT 2026
- Pichia 2026
- Future Labs Live 2026
- BioProScale Sympposium 2026
- ASGCT 2026
- Eppendorf Automation Forum 2026
- ESACT 2026
-
-
-
-
- WHX Labs Dubai 2026
- analytica 2026
- Forum Labo 2026
- SLAS Europe 2026
- Forum Labo 2026 Bioprocess
- Bioprocessing Summit Europe 2026
- BioProcess International 2026
- Swiss Biotech Day 2025
- ISCT 2026
- Pichia 2026
- Future Labs Live 2026
- BioProScale Sympposium 2026
- ASGCT 2026
- Eppendorf Automation Forum 2026
- ESACT 2026
-
-
- All Centrifuges
- Benchtop Centrifuges
- Floor-Standing Centrifuges
- Refrigerated Centrifuges
- Microcentrifugeuses
- Centrifugeuses multi-fonctions
- Centrifugeuses haute vitesse
- Ultracentrifugeuses
- Concentrateur
- Produits IVD
- High-Speed and Ultracentrifuge Consumables
- Tubes
- Plaques
- Gestion des appareils
- Gestion des échantillons et des informations
-
- Pipetage manuel & distribution
- Mechanical Pipettes
- Connected Pipettes
- Multi-Channel Pipettes
- Positive Displacement Pipettes & Dispensers
- Pointes de pipette
- Bottle-Top Dispensers
- Pipette Controllers
- Accessoires
- Automates de pipetage
- Automation Consumables
- Automation Accessories
- Liquid Handler & Pipette Services
- CAR-T Cell Research and Development
Read more
Read less
CAR-T Cells: Breakthroughs in Cancer and Auto-Immune Therapies
Lire la suite
CAR-T Cell Development – The Future of Fighting Cancer
CAR-T cells, genetically engineered and equipped with specific receptors to target and combat cancer cells, are primarily divided into two categories: autologous and allogenic CAR-T cells. Hereby, autologous CAR-T cells derive from the patient’s own white blood cells and are reintroduced after modification, whereas allogenic CAR-T cells are designed as off-the-shelf solutions for use in different patients. However, both approaches have their challenges. The manufacturing process for autologous CAR-T cells is complex and costly, as each patient’s cells must be individually processed. Allogeneic CAR-T cells, on the other hand, currently do not have the same safety profile, necessitating further research to address these issues.
Downloads